Underwriters Shouldn't Be Reading Lab Reports
Underwriters Shouldn't Be Reading Lab Reports The Manual COA Problem Is Becoming One of the Biggest Compliance Gaps in Regulated Payment...
The promise of healthcare coverage for medical cannabis has long tantalized patients facing steep out-of-pocket costs for their treatments. Now, a new reimbursement program is offering a workaround that could provide meaningful financial relief—though it falls short of the comprehensive insurance coverage many patients have been hoping for.
According to reporting by MJBizDaily, a recently announced program called Elevated States could reimburse medical marijuana patients up to $175 per month for cannabis products and related doctor visits. The American Council of Cannabis Medicine (ACCM) is administering this arrangement, which major insurers including Cigna, Detego Health, and Envita Health are incorporating into some healthcare packages across the 38 states where medical marijuana is legal.
Gennaro Luce, CEO of EM2P2, the digital healthcare platform behind the initiative, explained that these potential cost savings arrive at a particularly opportune moment. With overall healthcare costs projected to increase significantly amid ongoing policy debates in Washington, competitive reimbursement options for cannabis-centered therapies could provide welcome financial relief for patients managing chronic conditions.
Despite the promising headlines, patient advocacy leaders are urging caution about overstating what these programs actually deliver. Steph Sherer, founder and president of Americans for Safe Access, emphasizes that what's being marketed as "coverage" often amounts to employee discount programs—more comparable to gym membership perks or acupuncture discounts than traditional insurance benefits.
The distinction matters significantly for patients. True insurance coverage would integrate medical cannabis into comprehensive healthcare plans, with predictable copays, deductibles, and coverage limits. Current reimbursement programs, while helpful, operate more like rebate systems where patients still pay upfront costs and then seek partial reimbursement afterward.
Doug Benns, a consultant on the ACCM's executive committee, notes that reimbursement structures vary considerably among participating insurers. Some will cover doctor visits, others will reimburse dispensary purchases, and some will cover both. By the time open enrollment begins November 1st, Benns estimates approximately 15 insurance companies will participate in the program.
The fundamental barrier to authentic insurance coverage remains federal cannabis prohibition. Despite medical marijuana's widespread acceptance—38 states have legalized medical programs, and courts have required states to cover cannabis treatment in workers' compensation cases—lingering Schedule I classification makes insurers extremely hesitant about touching cannabis.
This creates a challenging compliance environment for everyone involved. Insurance companies cannot risk violating federal law, even when state regulations explicitly authorize medical cannabis use. Healthcare providers must balance patient care with regulatory uncertainty. And patients find themselves navigating a confusing patchwork of limited coverage options that vary dramatically by state, employer, and insurance carrier.
For businesses operating in this environment, robust quality management systems become absolutely essential. Cannabis companies must maintain impeccable documentation standards, comprehensive Certificate of Analysis management, and transparent supply chain oversight. When insurance companies do engage with medical cannabis—even through limited reimbursement programs—they inevitably scrutinize product quality, testing standards, and regulatory compliance.
Any reimbursement mechanism for medical marijuana patients could significantly strengthen medical cannabis markets, which have suffered as adult-use programs expanded. Data from the Marijuana Policy Project shows that medical marijuana patient numbers typically decrease by roughly one-third after recreational sales launch in a state.
Kevin McCarty, compliance director at Kolas, which operates six retail locations in Sacramento, California, reports that medical marijuana patients currently account for only about 5% of their customer base. However, he projects patient numbers could increase by approximately 5% when reimbursement options become available. With economic pressures tightening household budgets, the ability to receive reimbursement for medical cannabis could prove transformative for patients who have switched to cheaper recreational markets or abandoned cannabis therapy entirely due to cost concerns.
Federal rescheduling could eventually unlock broader insurance coverage possibilities. President Donald Trump has indicated willingness to consider moving cannabis to Schedule III of the Controlled Substances Act, which would officially recognize marijuana's medical value. This regulatory shift could encourage significant changes that would allow Medicaid or the Veterans Health Administration to cover medical marijuana, potentially creating a pathway for private insurers to follow suit.
Dr. Mikhail Kogan of the GW Center for Integrative Medicine in Washington, D.C., argues that covering medical marijuana would save the healthcare system substantial money while potentially preventing 50,000 deaths annually among patients prescribed dangerous prescription drugs. He points to the stark cost comparison between pharmaceutical-grade CBD drug Epidiolex, which costs $30,000 annually (covered by insurance for 97% of patients with Dravet syndrome and TSC), and high-quality CBD from reputable distributors, which can cost as little as $300 per year.
Sherer emphasizes that patient welfare must remain central to any discussion about insurance coverage and reimbursement programs. While businesses naturally view reimbursement mechanisms as market opportunities, she stresses that meaningful progress requires integrating cannabis into the broader healthcare system in ways that genuinely benefit patients rather than simply creating new revenue streams.
The quality management infrastructure supporting these emerging reimbursement programs will prove critical. Insurance companies examining medical cannabis providers will demand rigorous compliance documentation, secure COA management, and transparent quality control processes. Companies using advanced quality management systems position themselves more favorably as these reimbursement mechanisms expand.
As medical cannabis reimbursement programs expand and federal policy potentially shifts, maintaining comprehensive quality management infrastructure becomes increasingly vital. Qredible's Q-Trust system provides cannabis businesses with the rigorous compliance documentation, secure Certificate of Analysis management, and transparent supply chain oversight that insurers and regulators demand. Contact our team today to learn how our blockchain-secured platform can position your medical cannabis operation for success in this evolving reimbursement environment.
Source: This article is based on reporting by Margaret Jackson for MJBizDaily, published October 27, 2025.
